Retatrutide 1-Year Results

The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) ran for 48 weeks -- long enough to capture the full arc of weight loss from first injection to plateau. The headline number is extraordinary: up to 24% body weight loss at the highest dose (12mg). But the full picture extends far beyond the scale, encompassing metabolic transformation, body composition changes, cardiovascular risk reduction, and quality-of-life improvements that collectively represent the most comprehensive pharmacological intervention for obesity ever documented.

Weight Loss at 48 Weeks by Dose

Phase 2 tested multiple doses, demonstrating a clear dose-response relationship. Lower doses (1mg) produced approximately 8-9% weight loss. Mid-range doses (4mg) produced approximately 17-18% weight loss. Higher doses (8mg) produced approximately 22-23% weight loss. The highest dose (12mg) produced approximately 24% weight loss. Even the lowest doses exceeded semaglutide's maximum efficacy, while the highest dose surpassed tirzepatide's results.

Beyond the Scale: 1-Year Health Transformation

The metabolic improvements at 1 year are as impressive as the weight loss itself. Participants with type 2 diabetes showed HbA1c improvements approaching 2%, with many achieving near-normal glucose levels. Blood pressure reductions of 8-12 mmHg systolic were observed. Liver fat decreased by 80%+ in some participants -- a potentially transformative result for fatty liver disease. Inflammatory markers decreased substantially. Waist circumference decreased by 5-8 inches on average. These changes collectively represent a massive reduction in cardiovascular disease risk, the leading cause of death in patients with obesity.

What Happens After Year 1

The critical question after a successful first year is: what now? Options include continuing retatrutide at the current dose for ongoing weight maintenance, reducing the dose to the minimum effective level for maintenance, transitioning to lifestyle management alone (higher regain risk), or continuing indefinitely at therapeutic doses (emerging consensus for chronic disease management). Most obesity medicine experts increasingly view pharmacological weight management as a chronic treatment, similar to blood pressure or diabetes medications, rather than a time-limited intervention.

Comparing to Other Interventions

Retatrutide's 1-year results place it in unprecedented territory for pharmacological weight loss. It produces approximately 7-9% more weight loss than semaglutide (15-17%), 2-4% more than tirzepatide (20-22%), and approaches gastric sleeve surgery (25-30%) without surgical risk. Only gastric bypass (30-35%) consistently exceeds retatrutide's results, and retatrutide lacks the permanent anatomical changes, nutritional deficiency risks, and surgical complications of that procedure.

To begin your weight loss journey with currently available treatments, visit our treatments page.